a Multifaceted Program for Improving Quality of Care in ICU
NCT ID: NCT00461461
Last Updated: 2009-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2117 participants
INTERVENTIONAL
2007-01-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: The intervention program will decrease the incidence of the predefined AEs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring the Use of AI-Assisted Video Monitoring to Predict Accidental Events in ICU Patients
NCT07307521
Evaluating the Effectiveness of an Electronic Medical Transfer Tool to Improve Communication During Transfers From ICU
NCT03590002
ICU Cockpit Apps: Interventional Study With First ICU Cockpit Software Applications
NCT04748289
MONITOR-IC Post ICU Care Study
NCT05066984
Relevance and Nuisances of Respiratory Rate Alarm Generated by Multi-parametric Monitors in Non Ventilated ICU Patients
NCT02908659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Error in insulin administration Insulin not given exactly as prescribed (including in the written protocol used in the ICU). The error may be a planning error or an implementation error regarding the nature of the insulin, dosage, preparation modalities, or administration modalities. Insulin therapy requires monitoring of capillary blood glucose levels.
2. Error in anticoagulant prescription Non respect of the recommendations about indications, dosages, administration modalities, contraindications, drug-drug interactions, and laboratory monitoring using the VIDAL (French Drug Compendium), learned societies, ICU protocols, and local drug committees. Either unfractionated heparin or low-molecular-weight heparin may be involved
3. Error in anticoagulant administration Anticoagulant not given exactly as prescribed. The error may be a planning error or an implementation error regarding the nature of the anticoagulant, dosage, preparation modalities, administration modalities, dosing times, or dosing intervals. Either unfractionated heparin or low-molecular-weight heparin may be involved.
4. Unplanned catheter removal Unplanned complete removal of a central venous catheter by the patient or by staff while caring for the patient.
5. Unplanned extubation Extubation not planned by the physicians. Unplanned extubations can be categorized as self-extubation by the patient, or accidental extubation for technical reasons (porosity, section of the balloon, poorly secured tube), and during patient care (bathing, taking radiographs, transportation, care).
Randomization procedure We will use a multicenter cluster randomized design to assess the effectiveness of a multifaceted intervention. Our statistician will randomly assign each unit to compliance with ICU guidelines as usual or implementation of the multifaceted intervention to prevent one of the AEs. Randomization will occur at the ICU level. Units that do not use the intervention program will serve as controls. The randomization procedure will be repeated every 2 1/2 months for a total of four 21/2-month periods in 2007-2008. During the month of January, the study will be prepared at each site, where a clinical research assistant will be trained in the use of RheaTM data collection software (http://outcomerea.org/rhea/install).
In the Iatroref II study, anticoagulant prescription or administration errors occurred in 59/1377 (about 6%) patients, insulin administration errors in more than 20% of patients, and unplanned catheter or endotracheal tube removal in 4% of patients. For this study, we collapsed unplanned catheter removal and unplanned extubation into a single group and administration error and prescription error of anticiagulant in another single group. Assuming that more than 2400 patients will be admitted to the four study ICUs during the study period, the study would have greater than 80% power for detecting a 4% absolute decrease in anticoagulant errors, a 3% absolute decrease in unplanned catheter or endotracheal tube removal, and a 10% absolute decrease in insulin treatment errors. We will use the two-sided score test for comparisons (Farrington and Manning). P levels ≤0.05 will be considered statistically significant.
Interventions In each study ICU, a physician trained in clinical research and a a clinical research assistant will prepare the study during the two weeks preceding randomization. The intervention for each AEs will include three components: meeting with the ICU nurses and physicians, distribution of educational materials including a pocket card showing the recommendations about prevention of each AE, and quality improvement sessions twice a month. At each site, the physician trained in clinical research and the clinical research assistant will lead feedback meetings with the ICU staff every 2 weeks 1) to provide feedback about AEs that occurred in the last 2 weeks, 2) to review compliance with recommendations on the pocket card, and 3) to analyze the causes of AEs and suggest practice changes if appropriate. A report on each meeting will be drafted.
Intervention for insulin administration errors
1. Meeting with the ICU staff to discuss the epidemiology of patients admitted with diabetes mellitus outside the ICU, the pathophysiology of insulin resistance in ICU patients, and clinical studies of glycemic control and mortality in wards and ICUs.
2. Pocket card showing how and why to control blood glucose and giving the guidelines for controlling blood glucose levels with insulin infusions according to the protocol in each study ICU.
3. Feedback meeting twice a month on insulin administration errors in the unit, preventability, and appropriate changes in insulin treatment procedures.
Intervention for anticoagulant administration errors
1. Meeting with the ICU staff to discuss the pathophysiology of anticoagulants (heparin and HBPM), indications, AEs, and specific problems in the ICU (e.g., use during dialysis and in patients with renal failure).
2. Pocket card showing the nature of the anticoagulants, AEs, route of administration (IV or enteral), specific problems in the ICU (e.g., use during dialysis and in patients with renal failure).
3. Feedback meeting twice a month on anticoagulant administration errors in the unit, causes of noncompliance with prescriptions, and preventability.
Intervention for anticoagulant prescription errors
1. Meeting with the ICU staff to discuss the pathophysiology of anticoagulants (heparin and HBPM), indications, AEs, and specific problems in the ICU (e.g., use during dialysis and in patients with renal failure).
2. Pocket cards with the nature of the anticoagulants, indications, dosage, route of administration, and Aes, as recommended by the French Society for Anesthesiology in 2005 in a consensus conference.
3. Feedback meeting twice a month on anticoagulant prescription errors in the unit, causes of noncompliance with recommendations, and preventability.
Intervention for unplanned extubation and catheter removal
1. Meeting with the ICU staff to discuss the epidemiology, risk factors, mortality, and prevention of unplanned extubation and catheter
2. Pocket card showing methods for securing catheters and endotracheal tubes, the sedation protocol, and the weaning protocol of each ICU.
3. Feedback meeting twice a month on occurrence of these AEs in the unit, causes, and preventability
Study population All patients admitted to the four study ICUs after January, 2007 will be included. No patients will be excluded. The study has been submitted to the appropriate ethics committee.
Data collection Patients Data are collected in the Outcomerea database. For each patient, the clinical research assistant will complete a case-report form on a computer using data capture software (Rhea) then will import all records to the Outcomerea database. The following information will be recorded prospectively: demographic characteristics (age, sex, and body mass index); underlying diseases using the Knaus classification \[8\]; admission category (medical, scheduled surgery, or unscheduled surgery), invasive procedures (arterial or venous central catheter, Swan-Ganz catheter, and endotracheal intubation), nosocomial infections (ventilator-associated pneumonia, nosocomial bacteremia, urinary tract infections, surgical site infections, and sinusitis), and decisions to withhold and/or withdraw life-sustaining treatments. The location of the patient prior to ICU admission will be recorded, with transfer from wards being defined as admission to the same hospital or another hospital before ICU admission. Severity of illness will be recorded at admission and once a day thereafter. Day 1 is the interval from admission to 8 A.M. on the next day; all other days are calendar days from 8 A.M. to 8 A.M. The Simplified Acute Physiology Score (SAPS II) \[9\] at admission and the Logistic Organ Dysfunction (LOD) \[10\] score are computed using the worst physical and laboratory data during the first 24 hours in the ICU. Duration of stays in the ICU and acute-care hospital and vital status at ICU and hospital discharge will be recorded.
Adverse events All AEs will be collected during all four periods, regardless of the intervention being implemented. For each AE, Rhea software will be used to collect the date and time of occurrence, clinical consequences (from a predefined list), therapeutic consequences (from a predefined list), preventability, severity, and relation with death on a five-item scale (excluded, very less unlikely, less unlikely, unlikely, likely, certainly). An open box will be available for description of the AEs if needed.
Statistical analysis A hierarchical (patients/center) logistic model will be used to evaluate the impact of each intervention. The intervention, as well as interactions between periods and specific interventions, will be taken into account.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
meeting nurses / physicians, quality improvement sessions
For each iatrogenic indicator, the interventions are:
1. Meeting with the ICU staff to discuss the epidemiology of patients on each theme.
2. Pocket card with guidelines on the theme and ICU protocol in each study ICU.
3. Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Outcomerea Group for Intensive Care Research
UNKNOWN
the Regional Direction of Clinical Research
UNKNOWN
the High Health Authority
UNKNOWN
Fondation Hôpital Saint-Joseph
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Soufir Lilia, MD
Role: PRINCIPAL_INVESTIGATOR
Fondation Hôpital Saint-Joseph
Garrouste Maité, MD
Role: PRINCIPAL_INVESTIGATOR
Fondation Hôpital Saint-Joseph
Timsit Jean Francois, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Unité INSERM U 823 - Equipe "Epidémiologie des cancers et affections graves"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive Care Unit
Grenoble, , France
Medical and surgical Intensive Care unit
Paris, , France
Intensive Care Unit
Saint-Denis, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garrouste-Orgeas M, Soufir L, Tabah A, Schwebel C, Vesin A, Adrie C, Thuong M, Timsit JF; Outcomerea Study Group. A multifaceted program for improving quality of care in intensive care units: IATROREF study. Crit Care Med. 2012 Feb;40(2):468-76. doi: 10.1097/CCM.0b013e318232d94d.
Related Links
Access external resources that provide additional context or updates about the study.
Outcomerea association
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOM04-108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.